SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Boxlight Corp. is a technological company, which engages in developing, selling, and providing interactive classroom solutions for the global education market. It also designs, manufactures, and distributes interactive projectors, flat panel displays, touch projectors, touch boards, and MimioTeach through the Boxlight Group and Genesis brands. The company was founded by Herbert Myers and Sloan Myers in 1985 and is headquartered in Duluth, GA.

Boxlight Corporation - Ordinary Shares - Class A

Boxlight Corp

BOXL is trending due to a reported breakout potentially fueled by news of shipping Google EDLA-certified interactive displays. Community discussions revolve around short squeeze potential and high volatility. Some traders point to the company's history of dilution as a reason for caution, while others express optimism for a continued run.

AgriFORCE Growing Systems Ltd. is an agriculture technology company, which engages in the development and utilization of intellectual property (IP) assets for improvement. Its solutions include consulting, air and surface sterilization, and other projects. The company was founded on December 22, 2017 and is headquartered in Vancouver, Canada.

AgriFORCE Growing Systems ltd

AgriFORCE is trending due to news of a potential $550 million fundraising plan led by Anthony Scaramucci to acquire AVAX tokens, with the company potentially shifting its focus to crypto. The community is discussing the low float, potential for a squeeze, and comparing it to other recent runners. Some traders are also noting the company's planned name change to AVAX One.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid a critique amplified by Martin Shkreli questioning its technology's viability, sparking debate about its quantum advantage claims and long-term prospects. The community is weighing the criticism against positive developments like institutional buying and potential government support for quantum computing, resulting in volatile trading and discussions around short squeezes and future catalysts.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

BINI is trending due to a planned reverse stock split, its ninth since 2022, leading to concerns about value dilution and potential delisting. The community expresses frustration and accuses the company of being a scam, with many sharing stories of significant losses and criticizing management. Discussions also include the broader context of reverse splits and regulatory oversight.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to a Wedbush price target increase, driven by confidence in its nuclear growth strategy amid the AI revolution and potential policy tailwinds. Community members are debating the valuation, short interest, and the sustainability of the recent parabolic move, with some citing insider selling and potential dilution as concerns. The stock is also garnering attention as it broke ground on its first Aurora powerhouse in Idaho.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending due to its acquisition of Metsera, a company focused on obesity drugs, for up to $7.3 billion, a move that signals PFE's renewed interest in the weight-loss market. Community discussion revolves around the potential impact of this acquisition on competitors like Viking Therapeutics and the broader implications for Pfizer's pipeline and future growth strategy within the competitive pharmaceutical landscape.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to news of Mike Alfred joining the board, sparking excitement about his potential to accelerate growth and shape the company's strategy in digital assets and AI. The community is actively discussing how this appointment could enhance Bakkt's position in the fintech and crypto space. Bullish sentiment is also fueled by speculation around potential acquisitions and the company's moves in the crypto sector.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

Qualigen Therapeutics Inc

QLGN is trending due to a strategic $41 million investment from Faraday Future to pivot the company towards crypto and Web3, a move discussed by the community as a potential game-changer. Community chatter highlights the low float and potential for a squeeze, with some speculating on price targets. The stock's surge is attributed to this pivot and the potential it unlocks in the crypto space.

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Campbell, CA.

Semler Scientific Inc

Semler Scientific is trending due to discussions around a proposed merger with Strive, Inc. ($ASST) in an all-stock transaction that values SMLR at a significant premium, and community members are weighing the potential benefits and risks. Some traders are focusing on a lawsuit the company is facing, while others are eyeing the Bitcoin treasury aspect of the deal, especially as it relates to the valuation of both companies.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI ($TEM) is trending amid excitement surrounding its FDA clearance for its RNA-based XR IVD device, driving pre-market all-time highs. The community is discussing the potential for a short squeeze, fueled by a high short float, and some anticipate the stock reaching the $100 mark soon. Broader AI and healthcare sectors provide additional context, with some highlighting Pelosi's previous investment in the company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Lipocine Receives Updated Regulatory Guidance on LPCN 1154 Lipocine Receives Updated Regulatory Guidance on LPCN 1154 PR Newswire SALT LAKE CITY, Feb. 6, 2025 SALT LAKE CITY, Feb. 6, 2025...

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a...

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver...

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 PR Newswire SALT LAKE CITY...

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize...

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results PR Newswire SALT LAKE CITY, Oct. 10, 2024 Quantitative...

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO in the Gulf Cooperation Council (GCC) Countries

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO in the Gulf Cooperation Council (GCC) Countries Lipocine Announces Supply and Distribution Agreement with...

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition...

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference PR Newswire SALT LAKE CITY, Sept. 30, 2024 SALT...

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek PR Newswire SALT LAKE CITY, Sept. 5, 2024 Study...

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Lipocine Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

LPCN
Lipocine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LPCN News

LPCN Lipocine Inc